Search Within

Department of Medicine

Formats
  1. Journal Article (19618)
  2. Meeting Abstract (16046)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (236)
  10. Miscellaneous (90)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22348)
  2. Hematologic Malignancies, Division of (13287)
  3. Center for Hematologic Malignancies (11069)
  4. GSK Faculty (10653)
  5. Survivorship Research (9346)
  6. Division of Subspecialty Medicine (7554)

More Groups

People
  1. Robert Motzer (1249)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1118)
  2. 2024 (2291)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1398)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (902)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2896)
  5. Oxford University Press (2291)
  6. Nature Publishing Group (2121)

More Publishers

Results (39669)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Robustness of response: A new measure of response assessment: Its impact on metricies of response in colorectal cancer
    Meeting Abstract

    Wang, L.; Schwartz, L. H.; Mazumdar, M.; Smith, A.; Kemeny, N. E.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Toll like receptors in allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Waghmare, A. A.; Hubbard, V.; Van Den Brink, M.
    Journal of Investigative Medicine (2005)

    Fulltext@MSK | Save
  • Killer immunoglobulin-like receptor ligand (KIR-L) mismatched natural killer (NK) cells for relapsed myeloma
    Meeting Abstract

    Van Rhee, F.; Shi, J.; Szmania, S.; Rosen, N.; Moreno, A.; Walker, R.; Dupont, B.; Hsu, K.; Baxter-Lowe, L. A.; Campana, D.; more...
    Journal of Immunotherapy (2005)

    Fulltext@MSK | Save
  • Osteonecrosis of the jaw in patients with metastatic breast cancer
    Meeting Abstract

    Van Poznak, C. H.; Estilo, C. L.; Sauter, N. P.; Williams, T.; Tunick, S.; Halpern, J.; Hudis, C. A.; Huryn, J. M.
    Journal of Bone and Mineral Research (2005)

    Fulltext@MSK | Save
  • Life expectancy of patients with bone metastases from breast cancer: A retrospective, single institution review
    Meeting Abstract

    Van Poznak, C.; Martin, J.; Hudis, C.
    Cancer Treatment Reviews (2005)

    Fulltext@MSK | Save
  • Artificial antigen-presenting cells permit selective in vitro generation of CMV-specific T-cells of desired HLA allelic restriction for adoptive immunotherapy in recipients of HLA disparate allografts
    Meeting Abstract

    Trivedi, D.; Kollen, W. J.; Barnett, L.; Sadelain, M.; O'Reilly, R. J.
    Blood (2005)

    Fulltext@MSK | Save
  • Generation of CMV specific cytolytic CD4(+) and CD8(+) T-CELLS by sensitization with a single pentadecapeptide of CMV PP65 containing both MHC class I and class II epitopes
    Meeting Abstract

    Trivedi, D.; Koehne, G.; Barnett, L.; Doubrovina, E.; O'reilly, R.
    Biology of Blood and Marrow Transplantation (2005)

    Fulltext@MSK | Save
  • A phase II trial of letrozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hormone receptor-positive metastatic breast cancer
    Meeting Abstract

    Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Park, J.; Hudis, C.; more...
    Breast Cancer Research and Treatment (2005)

    Fulltext@MSK | Save
  • A feasibility study of an aromatase inhibitor (Al), letrozole (L) and the antibody to vascular endothelial growth factor (VEGF), bevacizurnab (B), in patients (pts) with hormone receptor-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Traina, T. A.; Dickler, M. N.; Caravelli, J. F.; Yeh, B. M.; Brogi, E.; Panageas, K.; Flores, S. A.; Norton, L.; Hudis, C.; Rugo, H.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save
  • Phase II trial of preoperative combined modality therapy for esophageal carcinoma: Induction cisplatin-irinotecan followed by concurrent cisplatinirinotecan and radiotherapy
    Meeting Abstract

    Tew, W. P.; Minsky, B.; Bains, M.; Rizk, N.; Rusch, V.; Kelsen, D. P.; Shah, M.; Kepler, S.; Gonen, M.; Ilson, D. H.
    Journal of Clinical Oncology (2005)

    Fulltext@MSK | Save